A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia

By afschroeder • September 9, 2025

Aribi A, Mannis GN, Madanat YF, Jonas BA, Dunavin N, Roboz GJ, Jeyakumar D, Garcia-Manero G, Liu H, Carraway HE, Saultz JN, Blum W, Schiller G, Huang T, Woodard P, Klencke B, Liao XC, Xiang H, Pollyea DA, DiNardo CD. A phase 1 study of IO-202, an anti-LILRB4 antibody, in chronic myelomonocytic leukemia and acute myeloid leukemia. Blood Neoplasia. 2025 Jun 9;2(4):100126. doi: 10.1016/j.bneo.2025.100126. PMID: 40919482; PMCID: PMC12409809.

Tags: Hematology/Oncology, Publications

Longitudinal Study on the Influence of Physical Activity in Managing Fatigue in Patients With Colorectal Cancer

Liu L, Kazemian E, Loroña NC, Shirazipour C, Gong J, Crowder SL, Nguyen N, Damerell V, Mooney K, Playdon MC, Ulrich CM, Li CI, Shibata[...]

Polycyclic aromatic hydrocarbons, gut microbiome composition, impulsivity, and attention covary in a human cohort

Hammer AJ, Kasschau KD, Davis Ii EW, Hoffman P, Johnson-Camacho K, Alexiev A, Anderson K, Shannon J, Marriott LK, Sharpton TJ. Polycyclic aromatic hydrocarbons, gut[...]

Tamibarotene with venetoclax and azacitidine in RARA+ acute myeloid leukemia: results from the SY-1425-202 study

Cluzeau T, Borate U, McMahon C, Fenaux P, Heiblig M, Peterlin P, Ball B, Chantepie S, Eghtedar A, Kambhampati S, Solh M, Torregrosa-Diaz J, Braun[...]